• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket

    8/18/23 8:22:56 AM ET
    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Banks
    Finance
    Get the next $AVTX alert in real time by email

    Gainers

    • Avalo Therapeutics Inc’s (NASDAQ:AVTX) shares surged 24.99% to 14.5 cents in pre-market trading after the company reported higher-than-expected quarterly earnings earlier this month.
    • Shares of Inhibikase Therapeutics Inc (NASDAQ:IKT) rose 8.45% to $2.31 in pre-market trading after the company announced the completion of its 501 bioequivalence study of IkT-001Pro.
    • PolyPid Ltd’s (NASDAQ:PYPD) stock climbed 7.24% to 37 cents in pre-market trading after JMP Securities analyst Roy Buchanan maintained a Buy rating.
    • WeTrade Group Inc’s (NASDAQ:WETG) shares spiked 6.97% to 37 cents in pre-market trading after the company submitted its Form 8-K on Wednesday.
    • Shares of Gaucho Group Holdings Inc (NASDAQ:VINO) rose 5.98% to 46.1 cents in pre-market trading after the company announced the debut of its premier sterling silver jewelry collection for Gaucho - Buenos Aires.
    • BIO-Key International Inc’s (NASDAQ:BKYI) stock climbed 5.14% to 63.1 cents in pre-market trading, reversing losses on disappointing second-quarter results.
    • Prosomnus Inc’s (NASDAQ:OSA) shares were trading higher by 5.0% at $1.05 in pre-market trading.
    • Shares of Renovaro Biosciences Inc (NASDAQ:REN) added 4.99% to reach $1.60 in pre-market trading after healthcare stocks recorded sharp losses on Wednesday.
    • Rail Vision Ltd’s (NASDAQ:RVSN) shares rose 4.82% to 43 cents in pre-market trading after deciding more than 3% since the beginning of the week.
    • Eargo Inc’s (NASDAQ:EAR) stock climbed 4.26% to $3.18 in pre-market trading after interim CEO Brownie William sold 490,664 shares.

    Losers

    • Modular Medical Inc’s (NASDAQ:MODD) shares tanked 15.44% to $1.03 in pre-market trading after the company announced a partnership with Phillips-Medisize to expand insulin delivery alternatives.
    • Shares of OpGen Inc (NASDAQ:OPGN) fell 13.16% to 18.15 cents in pre-market trading after HC Wainwright analysts downgraded the stock amid bankruptcy concerns.
    • Recruiter.Com Group Inc’s (NASDAQ:RCRT) stock declined by 12.66% to 26 cents in pre-market trading after the company announced registered direct and private placement offerings worth $1 million.
    • 1895 Bancorp of Wisconsin Inc’s (NASDAQ:BCOW) shares slid 8.23% to $7.25 in pre-market trading.
    • Shares of BioNexus Gene Lab Corp (NASDAQ:BGLC) fell 7.20% to $1.01 in pre-market trading.
    • F45 Training Holdings Inc’s (NYSE:FXLV) stock slid 5.65% to 13.21 cents in pre-market trading on delisting plans.
    • Lytus Technologies Holdings Ptv Ltd’s (NASDAQ:LYT) shares were down 5.41% to 35 cents in pre-market trading.
    • Shares of Sidus Space Inc (NASDAQ:SIDU) declined by 4.82% to 12.66 cents in pre-market trading after reporting its second-quarter earnings.
    • Smart for Life Inc’s (NASDAQ:SMFL) stock tanked 4.58% to $1.56 in pre-market trading.
    • Synlogic Inc’s (NASDAQ:SYBX) shares fell 4.56% to 50 cents in pre-market trading.

    Now Read This:

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $BCOW
    $BGLC
    $BKYI

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Inhibikase Therapeutics Inc.
    $IKT
    3/4/2026$4.00Buy
    Ladenburg Thalmann
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Inhibikase Therapeutics Inc.
    $IKT
    1/21/2026$6.00Buy
    BofA Securities
    Inhibikase Therapeutics Inc.
    $IKT
    12/26/2025$8.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Inhibikase Therapeutics Inc.
    $IKT
    12/11/2025$4.00Overweight
    Cantor Fitzgerald
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    More analyst ratings

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sands Capital Life Sciences Pulse Fund Ii, L.P. bought $2,999,999 worth of shares (2,068,965 units at $1.45) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    11/24/25 3:47:02 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Chief Executive Officer Depasquale Michael W bought $3,233 worth of shares (4,117 units at $0.79), increasing direct ownership by 4% to 102,775 units (SEC Form 4)

    4/A - BIO KEY INTERNATIONAL INC (0001019034) (Issuer)

    9/17/25 5:19:52 PM ET
    $BKYI
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Depasquale Michael W bought $3,233 worth of shares (4,117 units at $0.79), increasing direct ownership by 4% to 112,174 units (SEC Form 4)

    4 - BIO KEY INTERNATIONAL INC (0001019034) (Issuer)

    9/17/25 10:47:40 AM ET
    $BKYI
    Computer Software: Prepackaged Software
    Technology

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the "Inducement Plan"), effective as of March 31, 2026 (the "Effective Date"). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The

    4/3/26 2:01:00 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Only Mach 2+ Commercial Fleet in the World Is Now Testing Reusable Hypersonic Space Systems -- and the Pentagon Is Writing the Checks

    Issued on behalf of Starfighters Space, Inc.CAPE CANAVERAL, Fla., April 2, 2026 /CNW/ -- USA News Group News Commentary — The next arms race isn't being fought on the ground. It's being fought at 45,000 feet and Mach 2, in the stratosphere where hypersonic weapons are validated, reusable space systems are tested, and the gap between the United States and its adversaries is either closed or conceded. The Pentagon knows it. Congress knows it. And the capital flowing into the commercial aerospace sector right now reflects exactly that urgency. The U.S. Space Force is operating on a

    4/2/26 2:02:00 PM ET
    $ASTS
    $FJET
    $LUNR
    Telecommunications Equipment
    Consumer Discretionary
    Air Freight/Delivery Services
    Industrial Machinery/Components

    SIDUS SPACE REPORTS FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

    CAPE CANAVERAL, Fla., April 1, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) (the "Company" or "Sidus"), an innovative space and defense technology company, announced its financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. "2025 was a pivotal year for Sidus as we continued executing our long‑term strategy to build vertically integrated space and defense technology platforms," said Carol Craig, Founder and CEO of Sidus Space. "We expanded our on‑orbit capabilities with the successful launch and commissioning of Li

    4/1/26 6:01:00 AM ET
    $MTEK
    $SIDU
    Telecommunications Equipment
    Telecommunications

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Stein Robert Benjamin

    3 - PolyPid Ltd. (0001611842) (Issuer)

    4/6/26 8:01:42 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sullivan Christopher Ryan

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:14:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:13:22 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Inhibikase Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $4.00

    3/4/26 8:37:45 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    SEC Filings

    View All

    SEC Form 144 filed by Avalo Therapeutics Inc.

    144 - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 4:48:44 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 1:02:57 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Sidus Space Inc.

    10-K - Sidus Space Inc. (0001879726) (Filer)

    4/1/26 9:34:14 AM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Leadership Updates

    Live Leadership Updates

    View All

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Sidus Space Appoints Aerospace Executive Kelle Wendling to Board of Directors

    Veteran Space and Defense Leader Brings Three Decades of Government Contracting, ISR, and Space Systems Expertise to Sidus Board CAPE CANAVERAL, Fla., Jan. 5, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) ("Sidus" or the "Company"), an innovative space and defense technology company, today announced the appointment of accomplished aerospace and defense executive Kelle Wendling to its Board of Directors. Ms. Wendling brings more than three decades of executive leadership and government contracting experience across space systems, Intelligence, Surveillance and Reconnaissance (ISR), and Federal Aviation Administration (FAA) markets.

    1/5/26 8:30:00 AM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Financials

    Live finance-specific insights

    View All

    The Only Mach 2+ Commercial Fleet in the World Is Now Testing Reusable Hypersonic Space Systems -- and the Pentagon Is Writing the Checks

    Issued on behalf of Starfighters Space, Inc.CAPE CANAVERAL, Fla., April 2, 2026 /CNW/ -- USA News Group News Commentary — The next arms race isn't being fought on the ground. It's being fought at 45,000 feet and Mach 2, in the stratosphere where hypersonic weapons are validated, reusable space systems are tested, and the gap between the United States and its adversaries is either closed or conceded. The Pentagon knows it. Congress knows it. And the capital flowing into the commercial aerospace sector right now reflects exactly that urgency. The U.S. Space Force is operating on a

    4/2/26 2:02:00 PM ET
    $ASTS
    $FJET
    $LUNR
    Telecommunications Equipment
    Consumer Discretionary
    Air Freight/Delivery Services
    Industrial Machinery/Components

    SIDUS SPACE REPORTS FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

    CAPE CANAVERAL, Fla., April 1, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) (the "Company" or "Sidus"), an innovative space and defense technology company, announced its financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. "2025 was a pivotal year for Sidus as we continued executing our long‑term strategy to build vertically integrated space and defense technology platforms," said Carol Craig, Founder and CEO of Sidus Space. "We expanded our on‑orbit capabilities with the successful launch and commissioning of Li

    4/1/26 6:01:00 AM ET
    $MTEK
    $SIDU
    Telecommunications Equipment
    Telecommunications

    Rail Vision Announces Second Half and Full Year 2025 Financial Results

    Company presents strong balance sheet with year-end cash of approximately $20 million and zero debt Revenue up 14.4% year-over-year Ra'anana, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (NASDAQ:RVSN, FSE: C80)) ("Rail Vision" or the "Company"), an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems, today announced its financial results for the second half and full year ended December 31, 2025. The Company reported revenue growth and operational progress, strengthening its global market presence. "2025 was a transformative year for Rail Vision," said David BenDavid, Chief Executive Officer. "We advan

    3/31/26 4:02:00 PM ET
    $RVSN
    Railroads
    Industrials

    $AVTX
    $BCOW
    $BGLC
    $BKYI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    11/29/24 1:20:33 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care